ProCE Banner Activity

Expert Insights on Personalizing First-line Medication Therapy for Myelofibrosis

Clinical Thought

Read this commentary for expert insights on individualizing initial treatment of myelofibrosis with JAK inhibitors, including key strategies for reducing toxicities and supporting patients during therapy.

Released: June 23, 2023

Share

Faculty

Emily Hollinghurst

Emily Hollinghurst, PharmD, BCOP, CSP, APh

Assistant Professor
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GSK.

GSK

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Emily Hollinghurst, PharmD, BCOP, CSP, APh

Assistant Professor
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California

Emily Hollinghurst, PharmD, BCOP, CSP, APh: consultant/advisor/speaker: Eisai.

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.